Log In
Print
BCIQ
Print
Print this Print this
 

MK-5172

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionOral HCV NS3/4A protease complex inhibitor
Molecular Target HCV NS3/4A protease complex
Mechanism of ActionViral protease inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat HCV genotype 1 infection in non-cirrhotic, treatment-naïve patients; Treat HCV genotype 1 infection in non-cirrhotic, treatment-naïve patients with an IL-28 CC genotype; Treat HCV genotype 1 infection in treatment-naïve patients; Treat non-cirrhotic treatment-naïve patients with HCV genotype 2, 4, 5 and 6 infection
Regulatory Designation

U.S. - Breakthrough Therapy (Treat chronic HCV genotype 1 infection)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today